BPMC News and Press, Blueprint Medicines Corporation From 10/12/23

Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 PR Newswire CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call a...

2023-08-03 12:51:01 ET Summary Blueprint Medicines reported Q2 earnings with revenue of $57.6M (+57.6% Y/Y) but a net loss of $132.8M. The company unveiled a "precision at scale" growth strategy, targeting a $1.5 billion market, while emphasizing financial discipline and innovatio...

2023-08-03 11:40:42 ET Summary On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57...

2023-08-02 14:56:50 ET More on Blueprint Medicines Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation Blueprint Medicines Corporation ( BPMC ) Q2 2023 Earnings Call Transcript Blueprint Is Well-Positioned To Capitalize On ISM Market (M...

2023-08-02 13:00:51 ET Shares of Blueprint Medicines (NASDAQ: BPMC) were down more than 12% as of 12:45 p.m. on Wednesday after the healthcare company announced second-quarter earnings. The stock is still up more than 27% so far this year. Blueprint focuses on precision medi...

2023-08-02 11:52:06 ET Blueprint Medicines Corporation (BPMC) Q2 2023 Earnings Conference Call August 2, 2023, 8:00 am ET Company Participants Jenna Cohen - VP, IR Kate Haviland - CEO Philina Lee - CCO Fouad Namouni - President, R&D Mike Landsittel - ...

2023-08-02 07:16:09 ET Blueprint Medicines press release ( NASDAQ: BPMC ): Q2 GAAP EPS of -$2.19. Revenue of $57.6M (+57.6% Y/Y). Cost of Sales: Cost of sales was $2.3 million for the second quarter of 2023, as compared to $4.9 million for the second quarter of 2022. ...

Blueprint Medicines Reports Second Quarter 2023 Results PR Newswire -- Achieved $39.9 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 -- -- AYVAKIT approved b...

2023-08-01 13:45:10 ET Blueprint Medicines ( NASDAQ: BPMC ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$2.49 (vs. -$2.68 last year) and the consensus Revenue Estimate is $45.6M (+24.9% Y/Y). ...

Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023 PR Newswire CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call a...